Ultragenyx to Present at Upcoming Investor Conferences
Shalini Sharp, the company's Chief Financial Officer, will present at the Jefferies Healthcare Conferenceon Tuesday, June 4, 2019at 8:00 a.m. ETin New York, NY.
- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, President and Founder, will present at the
Goldman Sachs40th Annual Global Healthcare Conference on Thursday, June 13, 2019at 9:20 a.m. PTin Palos Verdes, CA.
The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's website at www.ultragenyx.com.
Investors & Media
Source: Ultragenyx Pharmaceutical Inc.